



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Rec'd PCT/PTC 02 JUN 2005
PCT/EP 2003 / 050928 #2

RECEIVED	
27 FEB 2004	
WIPO	PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02080054.6

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY

Anmeldung Nr:
Application no.: 02080054.6
Demande no:

Anmeldetag:
Date of filing: 03.12.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.
Velperweg 76
6824 BM Arnhem
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

New expression system from rhodococcus

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12N15/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK

New expression system from *Rhodococcus*

FIELD OF THE INVENTION

The invention concerns a promoter from *Rhodococcus*, more specifically *Rhodococcus erythropolis*, its regulation and the use of this promoter and its regulation as an expression system in heterologous applications.

BACKGROUND OF THE INVENTION

Actinomycetes, and especially bacteria of the genus *Rhodococcus* are renowned for their ability to metabolise complex molecules. Several species of *Rhodococcus* are able to degrade fuel, benzene, and even TNT and they are therefore widely studied in the field of microbiology which concerns the biochemical pathways and cell factories. Among the micro-organisms which oxidize natural and anthropogenic hydrocarbons and which are active participants in biogeochemical processes of the biosphere, e.g. contributing to producing a hydrocarbon-free atmosphere for the Earth, the genus *Rhodococcus* takes a predominant place.

Several *Rhodococcus* species also degrade natural phytosterols, which proceeds via the formation of steroids as pathway intermediates. These steroids may in turn be used as precursors in the production of pharmaceutically active compounds.

In order to produce pharmaceutical precursor compounds as pathway intermediates of microbes in high amounts, production strains are routinely transformed to optimise the expression of the genes of interest and/or block certain metabolic routes in order to achieve accumulation of the intermediates. Such transformation often involves the heterologous expression of proteins. With the increased use of *Rhodococcus* and other Actinomycetic bacteria (such as *Mycobacterium*, *Arthrobacter*, *Nocardia*, *Corynebacterium* and *Brevibacterium* species) for expression of heterologous proteins, there is a

growing need for improved regulation of such expression and for molecular tools.

Presently, mutant strains with desired properties are isolated by classical mutagenesis, such as UV irradiation, but these strains are often inadequate in industrial processes due to genetic instability and/or low bioconversion efficiencies. Molecularly defined (constructed) mutants would present important advantages over mutants generated by classical mutagenesis. Constructed mutants are genetically more stable and the introduced mutations represent well-defined genetic modifications.

Construction of genetically engineered strains by transformation may also make the use of chemical agents to block certain pathways obsolete. Chemical agents used to block enzyme activity mostly are often not reaction specific and may inhibit other important enzymatic reactions, which may have negative effects on bioconversion efficiency. The use of defined mutants by genetic engineering would overcome such problems.

An important enzyme in steroid metabolism, which can, for instance, be found in *Rhodococcus erythropolis*, is 3-ketosteroid Δ^1 -dehydrogenase (KSTD1, EC 1.3.99.4) the gene of which resides in the so-called *kstD1* locus (van der Geize, R. et al. 2000. Appl. Environ. Microbiol. 66: 2029-2036).

Although it is known that molecular organization of steroid catabolic genes may differ between different *Rhodococcus* species, homologues of this gene have been found in several other bacteria, such as *Arthrobacter simplex*, *Pseudomonas* spp., *Nocardia restrictus*, *Nocardia corallina*, *Nocardia opaca* and *Mycobacterium fortuitum*. The sequence of the *kstD* gene of *Rhodococcus erythropolis* strain SQ1 has been disclosed by Van der Geize et al. in WO 01/81050 and is depicted in SEQ ID NO:1.

From the same bacterial strain an isoenzyme KSTD2 with its corresponding gene *kstD2*, is known. Disruption of the *kstD1* gene has shown not to abolish 3-ketosteroid Δ^1 -dehydrogenase (KSTD) activity completely and

activity remains due to the presence of the isoenzyme (Van der Geize et al., 2002. Microbiology 148:3285-3292; WO 01/31050).

5 KSTD activity is essential for steroid nucleus degradation and *kstD* gene inactivation is needed to accumulate steroid intermediates. Inactivation of genes is a powerful tool for analysing gene function and for introducing metabolic blocks. Gene disruption with a non-replicative vector carrying a selectable marker is the commonly used method for gene inactivation.

10 It was found that wild-type KSTD activity in gene disruption mutant *R. erythropolis* SDH420 can be induced by the application of 3-keto- Δ^4 -steroids, such as 4-androstene-3,17-dione, indicating the presence of a steroid-dependent regulatory mechanism. Upstream of the *kstD* gene locus, a gene (ORF2) was identified whose function was hitherto unknown, but was described as a putative regulatory gene carrying the consensus sequence of repressor proteins of the TetR family (Van der Geize, R. et al. 2000. Appl. Environ. Microbiol. 66:2029-2036).

15 It has now been found that a promoter for the *kstD1* gene resides in the *kstD* locus of *Rhodococcus erythropolis* and that this promoter is regulated through repression with the gene product of ORF2 of the bacterium, denominated *kstR* hereafter. It has now also been found that this repression of the *kstD* promoter by the *kstR* gene-product can be overcome by the induction of expression with steroidal compounds. This property of the combination of the *kstD* gene- *kstR* repressor system makes it particularly fit for expression of heterologous proteins in bacteria such as those of the family of Actinomycetes.

25 SUMMARY OF THE INVENTION

In one aspect, the invention relates to an isolated polynucleotide comprising a promoter from *Rhodococcus erythropolis*, characterised in that said promoter is the *kstD* promoter.

30 The polynucleotide can very advantageously be used as a controllable transcription activator. Said controlling function can be provided by providing

said isolated polynucleotide with a nucleotide sequence encoding a transcription regulator of said promoter. In the present invention, such a transcription regulator may be externally induced, such as by introduction of steroidal compounds.

5 In an alternative embodiment of the present invention the isolated polynucleotide may comprise the *kstR* gene or a homologue or a functional part thereof as the transcription regulator of the *kstD* promoter.

10 Since the isolated polynucleotide of the invention can very advantageously be used as a heterologous expression system, the polynucleotide of the invention may further comprise a nucleotide sequence encoding a polypeptide that is operably linked to said promoter.

15 In order to provide for selectable traits in the bacteria into which the expression system is transferred, the polynucleotide may further comprise such sequences that encode selectable markers, counter-selectable markers and/or reporter genes.

In another aspect, the invention relates to a recombinant vector comprising an isolated polynucleotide of the invention. Such a recombinant vector suitably comprises nucleotide sequences that represent multiple cloning sites.

20 The present invention also relates to a method for constructing a genetically modified strain of a micro-organism which micro-organism lacks the ability to degrade the steroid nucleus, the method comprising producing a polynucleotide according to the present invention and transforming the said strain with said polynucleotide.

25 In another aspect the invention relates to a host cell transformed with the recombinant vector of the invention. Said host cell is preferably a bacterium from the order of Actinomycetales. Very suitable host cells are bacteria belonging to the families of Actinomycetaceae, Corynebacterineae, Mycobacteriaceae, Nocardiaceae, Brevibacteriaceae, or Micrococcaceae and in
30 particular those of the genus *Rhodococcus*.

In another aspect, the invention relates to a method for producing a desired protein in a host cell, comprising transforming a host cell with a recombinant vector of the invention.

5 In another aspect, the invention relates to a microbial expression system comprising a polynucleotide of the invention.

In yet another aspect, the invention relates to a method for constitutive expression of a protein of interest comprising transforming a host cell with a polynucleotide construct wherein the expression of the coding region of said protein is under control of the *kstD* promoter.

10 In another aspect, the invention relates to a use of a steroid for the induction of expression of a heterologous protein, which expression is under control of the *kstD* promoter, said steroid lifting the repressor function exerted by the *kstR* gene product.

15

DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of the construction of mutagenic plasmid pREG104 for *kstR* unmarked gene deletion.

20 Figure 2 is a schematic representation of the *Rhodococcus* expression vector pRESX derived from pRESQ (Van der Geize, R. et al. 2002. Mol. Microbiol. 45:1007-1018). Closed solid curved bar indicates the *kstD* promoter region. Open solid curved bar indicates *Rhodococcus* genes encoding autonomous replication. *aphII* encodes kanamycine resistance.

25 DETAILED DESCRIPTION OF THE INVENTION

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes double- and single-stranded DNA and RNA.

30 The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by

virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature; or (2) is linked to a polynucleotide other than that to which it is linked in nature; or (3) does not occur in nature.

5 "Transformation" and "transforming", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be
10 integrated into the host cell genome.

By "host cell" is meant a cell which contains a vector and supports the replication and/or expression of the vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are bacterial cells of the order of
15 Actinomycetales.

As used herein, the term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to another control sequence and/or to a coding sequence is ligated in such a way
20 that transcription and/or expression of the coding sequence is achieved under conditions compatible with the control sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

25 As used herein "promoter" is a DNA sequence that directs the transcription of a (structural) gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a (structural) gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of

transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.

The term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as the modifications known in the art, both naturally occurring and non-naturally occurring.

As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is by deliberate human intervention at a different native genomic locus than in the native state. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, the promoter and the gene are not operably linked in nature. A heterologous protein may originate from a foreign species or, if from the same species, is produced through expression from a heterologous nucleic acid.

A "repressor protein" or "repressor" is a protein that is able to recognize and bind to a nucleotide sequence that is contained in a DNA sequence (operator) that is located 5'-ward of a structural gene. The binding of a repressor protein with its cognate operator results in the inhibition of the transcription of the structural gene.

An "enhancer" is a DNA regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

The term "isolated" refers to material, such as a nucleic acid, which is substantially or essentially free from components that normally accompany

or interact with it as found in its naturally occurring environment. An isolated DNA molecule is a fragment of DNA that has been separated and that is no longer integrated in the genomic DNA of the organism from which it is derived.

5 The term "expression" refers to the biosynthesis of a gene product.

An "expression vector" is a DNA molecule comprising a gene that is expressed in a host cell. Typically, gene expression is placed under the control of certain regulatory elements, including constitutive or inducible promoters, regulatory elements and/or enhancers. Such a gene is said to be "operably
10 linked to" the regulatory elements and its expression is said to be "under control of" the regulatory elements.

The term "selectable marker" refers to a polynucleotide sequence encoding a metabolic trait which allows for the separation of transgenic and non-transgenic organisms and mostly refers to the provision of antibiotic
15 resistance. A selectable marker is for example the *aphII* encoded kanamycin resistance marker.

The term "counter-selectable marker" refers to a polynucleotide sequence whose expression is lethal, instead of giving rise to resistance as is often the case for selectable markers. A counter-selectable marker is for
20 example the *sacB* gene encoding *B. subtilis* levansucrase the expression of which is lethal in the presence of sucrose.

As used herein, the term "reporter gene" means a gene that encodes a gene product that can be identified. Reporter genes include, but are not limited to, chloramphenicol acetyl transferase, [beta]-galactosidase, luciferase
25 and green fluorescence protein. Identification methods for the products of reporter genes include, but are not limited to, enzymatic assays and fluorimetric assays. Reporter genes and assays to detect their products are well known in the art and are described, for example in Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley
30 Interscience: New York (1987) and periodic updates.

The sequence denoted as ORF2 of *Rhodococcus*, which is depicted in SEQ ID NO:4, has been deemed to be part of the chromosomal gene cluster also harbouring the *kstD1* gene (Van der Geize, R. et al. 2000. Appl. Environ. Microbiol. 66:2029-2036), where it is said to encode a TetR type of repressor protein (denominated *kstR*). However, the circumstances under which the repressor function is exercised or lifted have never been disclosed up till now. Also, the relation between the repressor function of *kstR* and the promoter of the *kstD1* gene has hitherto not been established.

In *Arthrobacter simplex* a similar genomic composition of the *kstD* gene and a putative repressor coding ORF (denominated *kdsR*) has been described (Molnar, I. et al. 1995. Mol. Microbiol. 15:895-905). In this case, no relation between repressor protein and expression of the steroid enzyme has been established.

The promoter region of the *kstD1* gene has not been exactly determined. The region between the start codons of the *kstD1* gene and the start of the *kstR* gene (which lies in the reverse order compared to the *kstD1* gene) is a sequence of about 158 basepairs, which contains the promoter for the *kstD1* gene and presumably also the promoter for *kstR*. In case this promoter would be working bidirectionally, the expression of gene encoding the repressor protein can also be driven by the *kstD1* promoter.

The promoter according to the invention is the promoter driving expression of the *kstD* gene in *Rhodococcus* and it preferably comprises the nucleotide sequence of 158 base pairs according to SEQ ID NO: 3 or a shortened version thereof (e.g. deleted at the 5' end) which still possesses the functional capacity of a promoter, i.e. to drive the expression of a protein which expression it controls. How to arrive at promoter deletion mutants is well known in the art and also the experimentation needed to identify promoter activity for such a deletion mutant comprises no undue burden and is well known to a person skilled in the art. Techniques for polynucleotide manipulation useful for the practice of the present invention are described in a

variety of references, such as Molecular Cloning: A Laboratory Manual, 2nd Ed., Vol. 1-3, eds. Sambrook et al. Cold Spring Harbor Laboratory Press (1989) or Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates thereof.

One skilled in the art would know methods for identifying active fragments of *kstD* promoter, which methods could include, for example, the measurement of transcription of mRNA or the expression of a polypeptide from a reporter gene which requires the addition of a functional promoter. To determine the presence of active *kstD* promoter fragments that are capable of controlling transcription and/or expression of the coding sequence to which it is operably linked, the person skilled in the art will readily understand that a promoter functionality test can be performed therewith. Such a test may for instance comprise the operable linking of a promoter of the invention and a reporter gene in a vector, bringing the vector in a suitable host, exposing the host to conditions suitable for expression and determining the presence of the reporter gene product in order to determine promoter functionality.

While the nucleotide sequence of the promoter (including promoter elements) is given in SEQ ID NO:3, it is recognized that nucleotide substitutions can be made which do not affect the promoter or promoter element function.

One skilled in the art would recognize that point mutations and deletions can be made to the *kstD* promoter sequences disclosed herein without altering the ability of the sequence to activate transcription. In addition, active fragments of the *kstD* promoter can be obtained. Similar methods can be used for identifying other active fragments of the *kstD* promoter. Other methods for identifying an active fragment of the *kstD* promoter are routine and well known in the art. For example, overlapping fragments of the *kstD* promoter can be synthesized and cloned into a suitable expression vector to determine active *kstD* promoter fragments. Similarly,

point mutations can be introduced into the disclosed *kstD* promoter sequences using, for example, site-directed mutagenesis or by synthesizing sequences having random nucleotides at one or more predetermined positions.

The invention includes as an embodiment an isolated polynucleotide comprising a *kstD* promoter or active fragment thereof. These isolated polynucleotides contain less than about 50%, preferably less than about 70%, and more preferably less than about 90% of the chromosomal genetic material with which the *kstD* promoter is usually associated in nature. An isolated polynucleotide "consisting essentially of" a *kstD* promoter lacks other promoters derived from the chromosome on which *kstD* is located. This terminology of "isolated" and "consisting essentially of" is analogously applicable to the *kstR* repressor element. For example, an isolated polynucleotide consisting essentially of a *kstR* repressor lacks polynucleotide material such as enhancers or promoters, respectively, located on the chromosome on which *kstR* is located.

Isolated polynucleotides comprised of or consisting essentially of a *kstD* promoter, and coding for a *kstR* repressor or active fragments thereof, may be prepared by techniques known in the art (e.g., Sambrook, et al.). These techniques include, for example, using the sequence information provided herein to provide primers and probes to amplify by PCR specific regions of *kstD* genomic clones, or by chemical synthesis, or by recombinant means.

A recombinant polynucleotide comprised of a *kstD* promoter or active fragment thereof, as well as those which may be comprised of other *kstD* transcription regulatory elements described herein, may be prepared by any technique to those of skill in the art using the sequence information provided herein.

In the experimental section the promoter is shown to be regulated by the repressor protein, which is presumed to bind to the promoter and thus to inhibit the expression of the protein which it controls. A recombinant polynucleotide comprised of a *kstD* promoter may also be comprised of a coding

sequence for the *kstR* repressor (such as depicted in SEQ ID NO:4) causing repression of *kstD*-promoted gene transcription and providing a regulation mechanism that can be lifted by exposing the cells to an inducer such as described below.

5 A recombinant polynucleotide comprising a *kstD* promoter may also comprise a coding sequence to which the promoter is operably linked, causing transcription of the coding sequence under the control of the promoter. Coding sequences may encode either homologous or heterologous polypeptides. However, they may also encode other moieties which are desirable in their
10 transcribed form. For example, coding sequences may encode, *inter alia*, decoy polynucleotides that bind to transcription factors, anti-sense RNAs, and a variety of polypeptides that are of interest (e.g. viral proteins to serve as intracellular vaccines, proteins that serve as markers, etc.), polypeptides for commercial purposes that are to be expressed in cells that express *kstD*
15 proteins, and particularly proteins that are of use in regulation of cell metabolism and production of pharmaceutical precursors.

For extracellular expression of proteins under control of the promoter a signal sequence can be inserted between the promoter and the DNA coding for the gene of interest. Such a signal sequence is provided to
20 allow targeting of proteins to specific cellular compartments. Preferably this signal sequence is the signal sequence of the gene coding for cholesterol oxidase as present in *R. equi* and as deposited at Genbank under accession number AJ242746 (see also Navas, J. et al. 2001. J. Bacteriol. 183:4796-4805).

The promoter can be used in any host cell, but preferably in a
25 prokaryote host cell, more preferably a bacterium from the order of *Actinomycetales*, such as those bacteria belonging to families such as *Actinomycetaceae*, *Corynebacterineae*, *Mycobacteriaceae*, *Nocardiaceae*, *Brevibacteriaceae*, *Micrococcaceae* and the like. More preferably it will be a bacterium of the genus *Rhodococcus*, *Mycobacterium*, *Arthrobacter*, *Nocardia*,
30 *Corynebacterium* or *Brevibacterium*. Most preferably it is a bacterium of the

genus *Rhodococcus* such as a bacterial strain of the species *Rhodococcus aetherovorans*, *Rhodococcus coprophilus*, *Rhodococcus equi*, *Rhodococcus erythreus*, *Rhodococcus erythropolis*, *Rhodococcus fascians*, *Rhodococcus globerulus*, *Rhodococcus jostii*, *Rhodococcus koreensis*, *Rhodococcus maanshanensis*, *Rhodococcus marinonascens*, *Rhodococcus opacus*, *Rhodococcus percolatus*, *Rhodococcus pyridinivorans*, *Rhodococcus rhodnii*, *Rhodococcus rhodochrous*, *Rhodococcus rubber*, *Rhodococcus tukisamuensis*, *Rhodococcus wratislaviensis*, *Rhodococcus zopfii* and the like.

Also part of the invention is a bacterial host cell which is equipped with the promoter, without having the gene for the repressor protein. Preferably this host cell is the bacterium *Rhodococcus erythropolis* RG10 as deposited under number DSM 15231 with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen at October 9, 2002. In this bacterium, as is shown in Example 1, the gene coding for the suppressor protein has been deleted.

Such a host cell, in which the suppressor gene has been deleted can be used for the expression of proteins. Preferably (although it may be that the host cell still has its endogenous *kstD* promoter) a vector harbouring the *kstD* promoter of the invention which controls the expression of a protein of interest should be introduced in the cell. Constructing such a vector and transformation or transfection of such a vector into the host cell is common practice for those skilled in the art. In this way, as is shown in Example 1, the *kstD* promoter will be unrepressed and act as a constitutive promoter.

A host cell according to the invention comprising the isolated *kstD* promoter or an active fragment thereof is understood to include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

It is recognized that specific nucleotides or regions within the *kstD* promoter elements other than *kstR* may be identified as necessary for regulation. These regions of nucleotides may be located by fine structural dissection of the elements by analyzing the functional capacity of a large number of promoter mutants. Single base pair mutations can be generated utilizing polymerase chain reaction (PCR) technology. U.S. Pat. No. 4,683,202. Mutated promoter regions can be cloned back into reporter constructs using standard techniques and evaluated by transfection into appropriate cells and assayed for reporter gene function. This analysis will also identify nucleotide changes which do not affect promoter function.

A further aspect of the invention is to use the repressor and its inducibility for controlled expression by providing a cell with a sequence that codes for the repressor protein and a sequence coding for a protein that needs to be controllably expressed, where that sequence is operably linked to the *kstD* promoter. The sequence for the *kstR* repressor protein may be encompassed on the same expression construct as the *kstD* promoter-gene of interest construct, but it may also be on a different construct. It is also envisaged that the host cell already contains the repressor gene, either located on a plasmid or on the chromosome. Then, the expression system is established by transforming such a host cell with a construct harbouring the *kstD* promoter. Similarly, the host cell may already contain the promoter controlling the expression of a gene of interest. Addition of the gene coding for the repressor protein then would stop expression of the gene of interest when the repressor protein is produced and expression can be induced again by lifting the repressor function. Also, the expression of the *kstR* repressor sequence may be under the control of a constitutive promoter.

A further method for controlling expression of a gene of interest by the *kstD* - *kstR* system is by replacing the *kstD* gene which is normally under control of the *kstD* promoter by inserting the coding sequence of a gene of interest *in situ* behind the *kstD* promoter. This can be accomplished by

techniques which are commonly known within the art, such as homologous recombination and/or use of recombinases and their recognition sites such as the cre-lox system.

- The repression of the *kstD* promoter exerted by the *kstR* gene product can be lifted by addition of a steroid compound, with 3-keto- Δ^4 functionality. In particular such compounds as 4-androstene-3,17-dione (AD), 1,4-androstadiene-3,17-dione (ADD), estr-4-ene-3,17-dione, testosterone, progesterone, norgestrel, 7 α -methyl-norgestrel, 11-methylene-norgestrel, but also such compounds as pregnenolone and stanolone (17 β -OH-5 α -androstane-3-on), 19-OH-7-dehydro-androstene-3,17-dione and 9 α -hydroxy-4-androstene-3,17-dione (9OHAD) are able to lift *kstD* promoter repression.

- Alternative regulatory compounds may also be identified. For instance, cells expressing products of reporter genes under the control of a *kstD* promoter are useful for identifying agents that regulate the activity of a *kstD* promoter. Thus, host cells expressing a reporter gene product under the control of a *kstD* promoter are useful for screening and it is a further object of the invention to provide a method for identifying compounds that regulate the activity of a *kstD* promoter. The method includes exposing a cell containing a *kstD* promoter to at least one compound whose ability to modulate the activity of a *kstD* promoter is sought to be determined. The cells are then monitored for changes caused by the modulation.

EXAMPLES

- Example 1. Constitutive expression of *kstD* following *kstR* unmarked gene deletion

Mutagenic plasmid pREG104 was constructed for unmarked gene deletion of *kstR*, the gene encoding a transcription regulator of the *kstD* gene (encoding 3-ketosteroid Δ^1 -dehydrogenase KSTD1) in *Rhodococcus erythropolis* SQ1 (Fig. 1). Briefly, pSDH205 (Van der Geize, R. et al. 2000. Appl. Environ. Microbiol. 66:2029-2036) was digested with restriction enzymes *Nru*I and *Bal*I

followed by self-ligation, resulting in plasmid pREG108. An *EcoRI* DNA fragment of pREG108, containing the *kstR* gene deletion was subsequently cloned into *EcoRI* digested pK18mobsacB vector, resulting in pREG104. Unmarked *kstR* gene deletion mutant *R. erythropolis* RG10 was isolated from *R. erythropolis* SQ1 using pREG104 via the *sacB* counter-selection method as described (Van der Geize R. et al 2001. FEMS Microbiol. Lett. 205:197-202). Genuine *kstR* gene deletion was confirmed by the polymerase chain reaction (PCR) using forward primer (REG-FOR) 5'GGCGACGTTGCCGAGAATT 3' and reverse primer (REG-REV) 5'TCAGTGTCGTGAGAGATTCA 3'. A PCR amplicon of 618 bp was obtained with parent strain SQ1 genomic DNA (control). With genomic DNA of *kstR* gene deletion mutant strain RG10 the amplicon was reduced to 393 bp, confirming *kstR* gene deletion.

Constitutive *KstD1* expression was checked by growing cells of mutant strain RG10 and parent strain SQ1 in glucose (20 mM) mineral medium (1 g·l⁻¹ NH₄NO₃, 0.25 g·l⁻¹ K₂HPO₄, 0.25 g·l⁻¹ MgSO₄·7H₂O, 5 mg·l⁻¹ NaCl, 5 mg·l⁻¹ FeSO₄·7H₂O (pH 7.2)) for 3 days at 30°C followed by steroid induction for 5 hours (0.5 g·l⁻¹ 4-androstene-3,17-dione (AD)). As a control, cell cultures without steroid induction were used. AD was solubilized in DMSO (50 mg·ml⁻¹) and added to the autoclaved medium. Cell pellets (30 min; 7,300 xg; 4°C) were washed with 200 ml phosphate buffer (KH₂PO₄ 2.72 g·l⁻¹; K₃HPO₄ 3.48 g·l⁻¹; MgSO₄·7H₂O 2.46 g·l⁻¹; pH 7.2). Washed cell suspensions (5 ml) were disrupted by double passage through a French pressure cell (140 Mpa). Cell extracts were centrifuged for 20 min at 25,000 xg to remove cell debris. Expression of *kstD* was checked by native polyacrylamide gel electrophoresis (PAGE) stained for KSTD activity (Van der Geize, R. et al 2000. Appl. Environ. Microbiol. 66:2029-2036) (Table 1). A KSTD1 activity band was found with cell free extracts prepared from non-induced cells of strain RG10, indicating that *kstR* gene deletion results in constitutive expression of the *kstD* gene (Table 1).

Table 1. Constitutive *kstD* expression upon *kstR* unmarked gene deletion checked by native PAGE stained for KSTD1 activity.

steroid induction (AD or 9OHAD)	<i>kstD</i> expression	
	parent strain SQ1	<i>kstR</i> mutant strain RG10
-	-	+
+	+	+

Example 2. Constitutive expression of *KstD2* for microbial steroid Δ^1 -

5 dehydrogenation

A *kstR* gene deletion mutant strain of *R. erythropolis* RG9 (Van der Geize, R. et al. 2002. Mol. Microbiol. 45:1007-1018) was constructed,

designated *R. erythropolis* RG17, using pREG104 (Fig.1, see example 1).

- 10 Strain RG17 thus is a *kstD kstD2 kshA1 kstR* quadruple gene deletion mutant, lacking 3-ketosteroid Δ^1 -dehydrogenase (KSTD1 and KSTD2) and 3-ketosteroid 9 α -hydroxylase (KSH) activities, in addition to the transcription regulator of the *kstD* promoter. Due to the *kstD kstD2 kshA* phenotype of this mutant, strain RG17 is completely blocked in metabolizing 4-androstene-3,17-dione (AD), 1,4-androstadiene-3,17-dione (ADD) and 9 α -hydroxy-4-androstene-

- 15 3,17-dione (9OHAD).

A *Rhodococcus* expression vector was constructed for the expression of genes under control of the *kstD* promoter of *R. erythropolis* SQ1 (Van der Geize, R. et al. 2000. Appl. Environ. Microbiol. 66:2029-2036). Using the *kstD* promoter, expression of genes in *R. erythropolis* mutant strains harboring a

- 20 *kstR* gene deletion will be constitutive due to the absence of the repressor of *kstD* expression. The *kstD* promoter region (158 bp) was isolated from *R. erythropolis* SQ1 chromosomal DNA by PCR amplification (25 cycles: 30s 95°C, 30s 64°C, 30s 72°C, using Taq polymerase) using forward primer 5'ATAAAGCTTATCGATTATGTGTCCCGGCCGCGAAC3' and reverse primer
- 25 5'ATAGGTACCATATGTGCGTCCTTACTCCAAGAGGG3'. A *NdeI* site (underlined) was incorporated in the amplicon to be able to clone genes of

interest precisely at the ATG startcodon of the *kstD* gene. The amplicon (175 bp) was blunt-ligated into the unique *Sna*BI restriction site of shuttle vector pRESQ (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018) and the resulting *Rhodococcus* expression vector was designated pRESX (Fig. 2).

- 5 The *kstD2* gene, encoding the KSTD2 isoenzyme in *R. erythropolis* SQ1, was isolated from chromosomal DNA of parent strain SQ1 by PCR (conditions: see above), using forward primer 5' GCGCATATGGCTAAGAATCAGGCACCC 3' (*Nde*I site underlined) and reverse primer 5' GCGGGATCCCTACTTCTCTGCTGCGTGATG 3' (*Bam*HI site underlined). The introduced *Nde*I and *Bam*HI sites were used to ligate the
- 10 *kstD2* amplicon into *Nde*I/*Bgl*II digested pRESX vector. The resulting plasmid was designated pRESX-KSTD2.

- Plasmid pRESX-KSTD2 was introduced into *R. erythropolis* strain RG17 by electrotransformation (Van der Geize, R. *et al.* 2000. Appl. Environ. Microbiol. 66:2029-2036) and one transformant was used for AD
- 15 biotransformation. Biotransformation of AD into ADD by KSTD2 was performed with cultures grown in 100 ml YG15 (15 g·l⁻¹ yeast extract, 15 g·l⁻¹ glucose) medium at 28 °C (200 rpm) in the presence of kanamycine (200 µg·ml⁻¹). After growth till late exponential phase (OD₆₀₀ of 5 to 9), AD (1 g·l⁻¹ in 0.1% [vol/vol] Tween80) was added and AD biotransformation into ADD was
- 20 followed for several days. For HPLC analysis, culture samples were diluted 5 times with methanol/water (70:30) and filtered (0.45 µm). Steroids were analyzed by HPLC (with a 250- by 8-mm reversed phase Lichrosorb 10RP18 column [Varian Chrompack International, Middelburg, The Netherlands], UV
- 25 detection at 254 nm, and a liquid phase of methanol-water [60:40] at 35 °C).

- Biotransformation experiments with cells of *R. erythropolis* strain RG17, harboring pRESX-KSTD2, showed the presence of KSTD2 steroid Δ^1 -dehydrogenase activity resulting in biotransformation of AD into ADD to near completion. In contrast, *Rhodococcus* mutants with wild type KSTD1 and
- 30 KSTD2 isoenzymes, but blocked in the KSH reaction, convert AD into ADD in

yields usually not exceeding 50%, probably due to regulatory mechanisms (Van der Geize, R. et al. 2002. Mol. Microbiol. 45:1007-1018).

5 **Example 3. Expression of *kshA* isogene *kshA2* complements the *kshA* mutant phenotype**

A homologue of the *kshA* gene of *R. erythropolis* SQ1 (Van der Geize, R. et al. 2002. Mol. Microbiol. 45:1007-1018) was identified following nucleotide sequencing of DNA fragments isolated by complementation experiments of UV-induced *Rhodococcus* mutants. *R. erythropolis* SQ1

10 contains at least two *kshA* isogenes, which were designated *kshA* and *kshA2*. *R. erythropolis* RG2, a *kshA* gene deletion mutant of *R. erythropolis* SQ1 (Van der Geize, R. et al. 2002. Mol. Microbiol. 45:1007-1018), does not show growth on mineral agar plates (1 g·l⁻¹ NH₄NO₃, 0.25 g·l⁻¹ K₂HPO₄, 0.25 g·l⁻¹ MgSO₄·7H₂O, 5 mg·l⁻¹ NaCl, 5 mg·l⁻¹ FeSO₄·7H₂O (pH 7.2), 1.5% agar) supplemented with AD (0.25 g·l⁻¹) as sole carbon and energy source. Thus,

15 *kshA2* is not expressed under these growing conditions in *R. erythropolis* RG2.

The *kshA2* gene was placed under control of the *kstD* promoter in pRESX. In order to achieve this, the *kshA2* gene was amplified from *R. erythropolis* chromosomal DNA as template by PCR using forward primer

20 5'GGCCATATGTTGACCACAGACGTGACGACC 3' (NdeI site underlined) and reverse primer 5'GCCACTAGTTCACTGCGCTGCTCCTGCAAG 3' (SpeI site underlined). The obtained *kshA2* amplicon was first ligated into *EcoRV* digested pBlueScript (II)KS (pKSH311) and subsequently subcloned as a NdeI / SpeI fragment into NdeI / SpeI digested pRESX, resulting in pKSH312.

25 Plasmid pKSH312 was introduced into *R. erythropolis* RG2 by electrotransformation and the resulting transformants were replica plated onto mineral agar medium containing 0.25 g·l⁻¹ of AD as sole carbon and energy source. All transformants were able to grow on AD mineral medium, indicating functional expression of *kshA2* under control of the *kstD* promoter

30 and complementation of the *kshA* mutant phenotype.

Example 4. Inducing steroids and constitutive expression.

In order to assess which steroids are able to induce the repressor-promoter system of the *KstD* gene, cell cultures of both *R. erythropolis* SQ1 (wildtype) and *R. erythropolis* RG10 (*kstR*-mutant) as described above were tested under inducing conditions with 1,4-androstadiene-3,17-dione (ADD), testosterone, progesterone, nordione, estron, 7 α -methyl-nordione, 11-methylene-nordione, stanolone (17 β OH-5 α -androstane-3-one), 19OH-7-dehydro-androstene-3,17-dione and pregnenolone were tested. 4-androstene-3,17-dione (AD) induction served as a positive control.

From induced cultures, cell free extracts were prepared as indicated above and tested for KSTD activity using DCPIP as an electron acceptor and AD as a substrate. With the exception of estron, it was found that all steroids tested were able to induce KSTD activity in *R. erythropolis* SQ1. The level of activity was not the same for all steroids tested. Controls on native gels confirmed that KSTD1 activity was indeed induced in all positive cases.

Further, it was investigated whether KSTD1 was constitutively expressed in *R. erythropolis* RG10. Cell free extracts were prepared from an AD-induced cell culture and from a non-induced cell culture. These extracts were tested for KSTD activity using DCPIP as an electron acceptor and AD as a substrate. For reasons of comparison, the same procedure was performed with *R. erythropolis* SQ1.

It was found that in both the induced as well as the non-induced culture of *R. erythropolis* RG10, KSTD activity was present. In *R. erythropolis* SQ1, on the other hand, KSTD activity was only detected in the AD-induced culture. Controls on native gels confirmed that KSTD1 activity was indeed induced in all positive cases.

Claims

1. An isolated polynucleotide comprising a promoter from *Rhodococcus*, characterised in that said promoter is the *kstD* promoter.
2. Polynucleotide according to claim 1, wherein said *Rhodococcus* is *Rhodococcus erythropolis*.
- 5 3. Polynucleotide according to claim 1 or 2, characterised in that it comprises nucleotide 1-158 from the sequence of SEQ ID NO:3 or a functional part thereof.
4. Polynucleotide according to claims 1-3, further comprising a nucleotide sequence encoding a transcription regulator of said promoter.
- 10 5. Polynucleotide according to claim 4, wherein the expression of said nucleotide sequence is controlled by steroidal compounds.
6. Polynucleotide according to claim 5, wherein said regulator comprises the *kstR* gene or a homologue or a functional part thereof.
7. Polynucleotide according to any one of the preceding claims, further
15 comprising a nucleotide sequence encoding a polypeptide that is operably linked to said promoter.
8. Polynucleotide according to any one of the preceding claims, further comprising a selectable marker, a counter-selectable marker and/or a reporter gene.
- 20 9. Polynucleotide according to any one of the preceding claims, further comprising a signal sequence.
10. Recombinant vector comprising a polynucleotide according to any one of the claims 1-9.
11. Recombinant vector according to claim 10, further comprising
25 a nucleotide sequence having multiple cloning sites.
12. Host cell transformed with the recombinant vector according to claim 10 or 11.

13. Host cell according to claim 12, wherein said host cell is a bacterium from the order of Actinomycetales.
14. Bacterial host cell according to claim 13, wherein said host cell is selected from bacteria belonging to the families of *Actinomycetaceae*,
5 *Corynebacterineae*, *Mycobacteriaceae*, *Nocardiaceae*, *Brevibacteriaceae*, or *Micrococcaceae*.
15. Bacterial host cell according to claim 13, wherein said host cell is selected from bacteria belonging to the genus *Rhodococcus*.
16. Bacterial host cell according to claim 13, wherein said host cell is the
10 bacterium *Rhodococcus erythropolis* RG10 as deposited under number DSM 15231 with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen.
17. Host cell according to any one of claims 12-16, which does not contain a functional *kstR* gene or a homologue or a functional part thereof.
- 15 18. Method for producing a desired protein in a host cell, comprising transforming a host cell with a recombinant vector of claims 10 or 11.
19. A microbial expression system comprising a polynucleotide according to any one of the claims 1-9.
20. Method for constitutive expression of a protein of interest
20 comprising transforming a host cell according to claim 17 with a polynucleotide construct wherein the expression of the coding region of said protein is under control of the *kstD* promoter.
21. Use of a steroid for the induction of expression of a heterologous protein, which expression is under control of the *kstD* promoter, said steroid
25 lifting the repressor function exerted by the *kstR* gene product.
22. Method for identifying compounds that regulate the activity of the *kstD* promoter comprising exposing a host cell according to any one of the claims 12-17 to at least one compound whose ability to modulate the activity of a *kstD* promoter is to be determined, and monitoring said cell for modulated
30 *kstD* promoter activity.

Title: New expression system from *Rhodococcus*

Abstract

The present invention provides an isolated polynucleotide comprising the *kstD* promoter from *Rhodococcus erythropolis*. The polynucleotide can very advantageously be used as a controllable transcription activator. Said controlling function can be provided by providing said isolated polynucleotide with a nucleotide sequence encoding a transcription regulator of said promoter. In the present invention, such a transcription regulator may be externally induced, such as by introduction of steroidal compounds. In an alternative embodiment of the present invention the isolated polynucleotide may comprise the *kstR* gene or a homologue or a functional part thereof as the transcription regulator of the *kstD* promoter.

24




Figure 1

25




Figure 2

SEQUENCE LISTING

<110> Akzo Nobel N.V.
 <120> New expression system from Rhodococcus

<130>

<140>

<141>

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 1543

<212> DNA

<213> Rhodococcus erythropolis

<220>

<221> CDS

<222> (1)..(1533)

<400> 1

atg cag gac tgg acc agc gag tgc gac gtg ttg gta gtc ggc tcc ggc	48
Met Gln Asp Trp Thr Ser Glu Cys Asp Val Leu Val Val Gly Ser Gly	15
1 5 10	
ggc gga gcg ctg acc ggc gca tat acc gcc gct gct cag gga ttg acg	96
Gly Gly Ala Leu Thr Gly Ala Tyr Thr Ala Ala Ala Gln Gly Leu Thr	30
20 25	
acg atc gtc ctg gag aaa acc gat cgt ttc ggc ggg acc tcc gcc tac	144
Thr Ile Val Leu Glu Lys Thr Asp Arg Phe Gly Gly Thr Ser Ala Tyr	45
35 40	
tgc ggc gcc tgc atc tgg ctg cca ggt acc cag gtg cag gaa cgc gcc	192
Ser Gly Ala Ser Ile Trp Leu Pro Gly Thr Gln Val Gln Glu Arg Ala	60
50 55	
gga ctt ccc gac tgc acc gag aat gcc cgc acc tat ctg cgc gcg ttg	240
Gly Leu Pro Asp Ser Thr Glu Asn Ala Arg Thr Tyr Leu Arg Ala Leu	80
65 70 75	
ctc ggt gac gcc gag tcc gag cgc cag gac gcc tac gtc gag acc gct	288
Leu Gly Asp Ala Glu Ser Glu Arg Gln Asp Ala Tyr Val Glu Thr Ala	95
85 90	
ccc gct gtc gtc gct cta ctg gag cag aac cgc aac atc gaa ttc gag	336
Pro Ala Val Val Ala Leu Leu Glu Gln Asn Pro Asn Ile Glu Phe Glu	110
100 105	
ttc cgt gcg ttc ccc gac tac tac aaa gcc gaa ggc cgg atg gac acg	384
Phe Arg Ala Phe Pro Asp Tyr Tyr Lys Ala Glu Gly Arg Met Asp Thr	125
115 120	
gga cgc tcc atc aac cct ctg gat ctg gat ccc gcc gac ata ggt gac	432
Gly Arg Ser Ile Asn Pro Leu Asp Leu Asp Pro Ala Asp Ile Gly Asp	140
130 135	
ctc gcc ggc aag gtg cgt ccg gaa ctg gac caa gac cgc acc ggt cag	480
Leu Ala Gly Lys Val Arg Pro Glu Leu Asp Gln Asp Arg Thr Gly Gln	160
145 150 155	

27

gat cat gct ccc ggc ccg atg atc ggt ggg cgc gca ctg atc ggc cgt 528
Asp His Ala Pro Gly Pro Met Ile Gly Gly Arg Ala Leu Ile Gly Arg 175
165 170

ctg ctg gcc gca gtt cag agc acc ggt aag gca gaa ctt cgc acc gaa 576
Leu Leu Ala Ala Val Gln Ser Thr Gly Lys Ala Glu Leu Arg Thr Glu 190
180 185

tcc gtc ctc acc tcc ctg atc gty gaa gac ggc cgt gtt gtc ggc gcc 624
Ser Val Leu Thr Ser Leu Ile Val Glu Asp Gly Arg Val Val Gly Ala 205
195 200

gag gtc gaa tcc ggc ggc gaa acc cag cga atc aag gcg aac cgc ggt 672
Glu Val Glu Ser Gly Gly Glu Thr Gln Arg Ile Lys Ala Asn Arg Gly 220
210 215

gtc ctg atg gca gca ggc ggc atc gaa ggc aac gcc gag atg cgt gag 720
Val Leu Met Ala Ala Gly Gly Ile Glu Gly Asn Ala Glu Met Arg Glu 240
225 230 235

cag gca gcc acc ccc ggc aag gcg atc tgg agt atg ggt ccc ttc ggc 768
Gln Ala Gly Thr Pro Gly Lys Ala Ile Trp Ser Met Gly Pro Phe Gly 255
245 250

gcc aac acc ggc gac gcg atc tct gcc ggt att gct gtc ggc gcc gca 816
Ala Asn Thr Gly Asp Ala Ile Ser Ala Gly Ile Ala Val Gly Gly Ala 270
260 265

aca gcc ttg ctc gat cag gcg tgg ttc tgc ccc ggc gtc gag cag ccc 864
Thr Ala Leu Leu Asp Gln Ala Trp Phe Cys Pro Gly Val Glu Gln Pro 285
275 290

gac gcc agc gcc gcc ttc atg gtc ggc gtt cgc ggt ggg ctc gtc gtc 912
Asp Gly Ser Ala Ala Phe Met Val Gly Val Arg Gly Gly Leu Val Val 300
290 295

gac agc gcc ggt gag cgc tac ctc aac gag tgg ott ccg tac gac cag 960
Asp Ser Ala Gly Glu Arg Tyr Leu Asn Glu Ser Leu Pro Tyr Asp Gln 320
305 310 315

ttc gga cga gcc atg gat gct cac gac gac aac ggt tct gcc gtg ccg 1008
Phe Gly Arg Ala Met Asp Ala His Asp Asp Asn Gly Ser Ala Val Pro 335
325 330

tcg ttc atg atc ttc gac tcy cgc gag ggt ggc gga ctg acc gcc atc 1056
Ser Phe Met Ile Phe Asp Ser Arg Glu Gly Gly Gly Leu Pro Ala Ile 350
340 345

tgc atc ccg aac acg gcg ccc gcc aag cac ctc gaa gcc gga acg tgg 1104
Cys Ile Pro Asn Thr Ala Pro Ala Lys His Leu Glu Ala Gly Thr Trp 365
355 360

gtc ggt gcc gac act ctc gaa gaa ctc gct gcc aag acc gga cta ccg 1152
Val Gly Ala Asp Thr Leu Glu Glu Leu Ala Ala Lys Thr Gly Leu Pro 380
370 375

gcc gac gca ttg cgc agc act gtc gaa aag ttc aac gat gcc gca aaa 1200
Ala Asp Ala Leu Arg Ser Thr Val Glu Lys Phe Asn Asp Ala Ala Lys 400
385 390

ctg gcc gtc gac gaa gag ttc cat cgc ggc gaa gac ccg tac gac gcg 1248
Leu Gly Val Asp Glu Glu Phe His Arg Gly Glu Asp Pro Tyr Asp Ala

28

405 410 415

ttc ttc tgc cca ccc aac ggc ggt ggc aat ggc gca ctg acg gcc atc 1296
Phe Phe Cys Pro Pro Asn Gly Gly Ala Asn Ala Ala Leu Thr Ala Ile
420 425 430

gag aac gga ccg ttc tac ggc gcc cgc atc gtc ctg agt gac ctg ggc 1344
Glu Asn Gly Pro Phe Tyr Ala Ala Arg Ile Val Leu Ser Asp Leu Gly
435 440 445

acc aag ggc gga ttg gtc acc gac gtc aac ggc cga gtc ctg cgt gct 1392
Thr Lys Gly Gly Leu Val Thr Asp Val Asn Gly Arg Val Leu Arg Ala
450 455 460

gac ggc agc gcc atc gac ggc ctg tac gcc gcc ggc aac acg agc gcg 1440
Asp Gly Ser Ala Ile Asp Gly Leu Tyr Ala Ala Gly Asn Thr Ser Ala
465 470 475 480

tca ctg agc ggc cgc ttc tac ccc ggc ccc gga gtt cca cto ggc acg 1488
Ser Leu Ser Gly Arg Phe Tyr Pro Gly Pro Gly Val Pro Leu Gly Thr
485 490 495

gct atg gtc ttc tgc tac cga gca gct cag gac atg ggc aag taa 1533
Ala Met Val Phe Ser Tyr Arg Ala Ala Gln Asp Met Ala Lys
500 505 510

cgcagttcaa 1543

<210> 2
<211> 511
<212> PRT
<213> Rhodococcus erythropolis

<400> 2
Met Gln Asp Trp Thr Ser Glu Cys Asp Val Leu Val Val Gly Ser Gly
1 5 10 15

Gly Gly Ala Leu Thr Gly Ala Tyr Thr Ala Ala Ala Gln Gly Leu Thr
20 25 30

Thr Ile Val Leu Glu Lys Thr Asp Arg Phe Gly Gly Thr Ser Ala Tyr
35 40 45

Ser Gly Ala Ser Ile Trp Leu Pro Gly Thr Gln Val Gln Glu Arg Ala
50 55 60

Gly Leu Pro Asp Ser Thr Glu Asn Ala Arg Thr Tyr Leu Arg Ala Leu
65 70 75 80

Leu Gly Asp Ala Glu Ser Glu Arg Gln Asp Ala Tyr Val Glu Thr Ala
85 90 95

Pro Ala Val Val Ala Leu Leu Glu Gln Asn Pro Asn Ile Glu Phe Glu
100 105 110

Phe Arg Ala Phe Pro Asp Tyr Tyr Lys Ala Glu Gly Arg Met Asp Thr
115 120 125

Gly Arg Ser Ile Asn Pro Leu Asp Leu Asp Pro Ala Asp Ile Gly Asp
130 135 140

Leu Ala Gly Lys Val Arg Pro Glu Leu Asp Gln Asp Arg Thr Gly Gln

29

145 130 155 160
 Asp His Ala Pro Gly Pro Met Ile Gly Gly Arg Ala Leu Ile Gly Arg
 165 170 175
 Leu Leu Ala Ala Val Gln Ser Thr Gly Lys Ala Glu Leu Arg Thr Glu
 180 185 190
 Ser Val Leu Thr Ser Leu Ile Val Glu Asp Gly Arg Val Val Gly Ala
 195 200 205
 Glu Val Glu Ser Gly Gly Glu Thr Gln Arg Ile Lys Ala Asn Arg Gly
 210 215 220
 Val Leu Met Ala Ala Gly Gly Ile Glu Gly Asn Ala Glu Met Arg Glu
 225 230 235 240
 Gln Ala Gly Thr Pro Gly Lys Ala Ile Trp Ser Met Gly Pro Phe Gly
 245 250 255
 Ala Asn Thr Gly Asp Ala Ile Ser Ala Gly Ile Ala Val Gly Gly Ala
 260 265 270
 Thr Ala Leu Leu Asp Gln Ala Trp Phe Cys Pro Gly Val Glu Gln Pro
 275 280 285
 Asp Gly Ser Ala Ala Phe Met Val Gly Val Arg Gly Gly Leu Val Val
 290 295 300
 Asp Ser Ala Gly Glu Arg Tyr Leu Asn Glu Ser Leu Pro Tyr Asp Gln
 305 310 315 320
 Phe Gly Arg Ala Met Asp Ala His Asp Asp Asn Gly Ser Ala Val Pro
 325 330 335
 Ser Phe Met Ile Phe Asp Ser Arg Glu Gly Gly Gly Leu Pro Ala Ile
 340 345 350
 Cys Ile Pro Asn Thr Ala Pro Ala Lys His Leu Glu Ala Gly Thr Trp
 355 360 365
 Val Gly Ala Asp Thr Leu Glu Glu Leu Ala Ala Lys Thr Gly Leu Pro
 370 375 380
 Ala Asp Ala Leu Arg Ser Thr Val Glu Lys Phe Asn Asp Ala Ala Lys
 385 390 395 400
 Leu Gly Val Asp Glu Glu Phe His Arg Gly Glu Asp Pro Tyr Asp Ala
 405 410 415
 Phe Phe Cys Pro Pro Asn Gly Gly Ala Asn Ala Ala Leu Thr Ala Ile
 420 425 430
 Glu Asn Gly Pro Phe Tyr Ala Ala Arg Ile Val Leu Ser Asp Leu Gly
 435 440 445
 Thr Lys Gly Gly Leu Val Thr Asp Val Asn Gly Arg Val Leu Arg Ala
 450 455 460
 Asp Gly Ser Ala Ile Asp Gly Leu Tyr Ala Ala Gly Asn Thr Ser Ala
 465 470 475 480
 Ser Leu Ser Gly Arg Phe Tyr Pro Gly Pro Gly Val Pro Leu Gly Thr

30

485

490

495

Ala Met Val Phe Ser Tyr Arg Ala Ala Gln Asp Met Ala Lys
500 505 510

<210> 3
<211> 158
<212> DNA
<213> Rhodococcus erythropolis

<400> 3
atcatcgatt atgtgtcccg gccgcgaacg accgcgctaa ttctctcacc tggaccaccc 60
atctcggcat attgcccgt cagtgggacc tggcatggcc ttccagtgcc gtgcggtatt 120
ccgtggacac cccacctct tggagtaagy acgcaatg 158

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 4
ggcgacgttg ccgagaatt 19

<210> 5
<211> 624
<212> DNA
<213> Rhodococcus erythropolis

<220>
<221> CDS
<222> (1)..(624)

<400> 5
atg ggg gcg acg ttg ccg aga att gcc gag gtc agg gac gct gct gag 48
Met Gly Ala Thr Leu Pro Arg Ile Ala Glu Val Arg Asp Ala Ala Glu
1 5 10 15
ccc agt tgg gac gag cag cgg gcg cgc cat gtg cgg atg ctg gaa gog 96
Pro Ser Ser Asp Glu Gln Arg Ala Arg His Val Arg Met Leu Glu Ala
20 25 30
gcc gcc gaa ttg ggg acc gag aaa gaa ctc tca cgg gtt cag atg cac 144
Ala Ala Glu Leu Gly Thr Gln Lys Glu Leu Ser Arg Val Gln Met His
35 40 45
gaa gtt gcc aag cgg gca ggc gtg gcc atc ggc act ctc tac cgc tat 192
Glu Val Ala Lys Arg Ala Gly Val Ala Ile Gly Thr Leu Tyr Arg Tyr
50 55 60
ttc cct tgg aag acg cac ctc ttc gtc gct gtg atg gtc gag cag atc 240
Phe Pro Ser Lys Thr His Leu Phe Val Ala Val Met Val Glu Gln Ile
65 70 75 80
gat cag atc ggc gac agt ttc gcc aag cat cag gtg cag tgg gcc aat 288
Asp Gln Ile Gly Asp Ser Phe Ala Lys His Gln Val Gln Ser Ala Asn

81

85	90	95	
ccg cag gac gcc gtg tac gag gtc ctg gtg cgc gcg act cgc ggg rta			336
Pro Gln Asp Ala Val Tyr Glu Val Leu Val Arg Ala Thr Arg Gly Leu			
100	105	110	
ctg cgt cgg ccg gcc ctt tcg act gcg atg ctg cag tgg tcc agt acc			384
Leu Arg Arg Pro Ala Leu Ser Thr Ala Met Leu Gln Ser Ser Ser Thr			
115	120	125	
gcc aac gtc gcg aag gtg ccg gac gtg ggc aag atc gat cgc ggc ttc			432
Ala Asn Val Ala Thr Val Pro Asp Val Gly Lys Ile Asp Arg Gly Phe			
130	135	140	
cgg cag atc atc ctc gat gcg gcc ggg atc gag aac ccg acc gag gaa			480
Arg Gln Ile Ile Leu Asp Ala Ala Gly Ile Glu Asn Pro Thr Glu Glu			
145	150	155	160
gac aac acc ggg ttg cgt ctg ctg atg cag ctg tgg ttc ggg gtc atc			528
Asp Asn Thr Gly Leu Arg Leu Leu Met Gln Leu Trp Phe Gly Val Ile			
165	170	175	
caa tgg tgc ctc aac ggt cga att tcc atc ccg gat gcg gag tac gac			576
Gln Ser Cys Leu Asn Gly Arg Ile Ser Ile Pro Asp Ala Glu Tyr Asp			
180	185	190	
atc cgc aag ggg tgc gac ctg ctt ctg gtg aat ctc tca cga cac tga			624
Ile Arg Lys Gly Cys Asp Leu Leu Leu Val Asn Leu Ser Arg His			
195	200	205	

<210> 6

<211> 208

<212> PRT

<213> Rhodococcus erythropolis

<400> 6

Met Gly Ala Thr Leu Pro Arg Ile Ala Glu Val Arg Asp Ala Ala Glu			
1	5	10	15
Pro Ser Ser Asp Glu Gln Arg Ala Arg His Val Arg Met Leu Glu Ala			
20	25	30	
Ala Ala Glu Leu Gly Thr Glu Lys Glu Leu Ser Arg Val Gln Met His			
35	40	45	
Glu Val Ala Lys Arg Ala Gly Val Ala Ile Gly Thr Leu Tyr Arg Tyr			
50	55	60	
Phe Pro Ser Lys Thr His Leu Phe Val Ala Val Met Val Glu Gln Ile			
65	70	75	80
Asp Gln Ile Gly Asp Ser Phe Ala Lys His Gln Val Gln Ser Ala Asn			
85	90	95	
Pro Gln Asp Ala Val Tyr Glu Val Leu Val Arg Ala Thr Arg Gly Leu			
100	105	110	
Leu Arg Arg Pro Ala Leu Ser Thr Ala Met Leu Gln Ser Ser Ser Thr			
115	120	125	
Ala Asn Val Ala Thr Val Pro Asp Val Gly Lys Ile Asp Arg Gly Phe			
130	135	140	

32

Arg Gln Ile Ile Leu Asp Ala Ala Gly Ile Glu Asn Pro Thr Glu Glu
 145 150 155 160
 Asp Asn Thr Gly Leu Arg Leu Leu Met Gln Leu Trp Phe Gly Val Ile
 165 170 175
 Gln Ser Cys Leu Asn Gly Arg Ile Ser Ile Pro Asp Ala Glu Tyr Asp
 180 185 190
 Ile Arg Lys Gly Cys Asp Leu Leu Leu Val Asn Leu Ser Arg His
 195 200 205

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 7
 tcagtgtcgt gagagattca 20

<210> 8
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 8
 ataaagctta tcgattatgt gtcccgccg cgaac 35

<210> 9
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 9
 araggtaacca tatgtgcgtc cttactccaa gaggg 35

<210> 10
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 10
 gcgcattatgg ctaagaatca ggcaccc 27

<210> 11

38

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 11
gggggatccc tacctcctg ctgagtgatg

30

<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 12
ggccatatgt tgaccacaga cgtgacgacc

30

<210> 13
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 13
gccactagtt cactgagctg ctctgcaag

30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.